Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 7/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL566664 | 0.88 | GRK6 (0.40) | HSP90AA1HSP90AB1DHFRADORA2AADORA2B | |
| SCHEMBL20275365 | 0.82 | TLR7 (0.53) | — | |
| SCHEMBL728835 | 0.77 | TLR7 (0.50) | — | |
| SCHEMBL566897 | 0.77 | TLR7 (0.53) | — | |
| SCHEMBL1844904 | 0.76 | TLR7 (0.58) | — | |
| SCHEMBL2387756 | 0.76 | TLR7 (0.49) | — | |
| SCHEMBL566854 | 0.76 | TLR7 (0.52) | — | |
| SCHEMBL1241960 | 0.76 | TLR7 (0.49) | — | |
| SCHEMBL1146459 | 0.76 | TLR7 (0.49) | ADORA2AADORA2B | |
| SCHEMBL12028528 | 0.75 | PIM1 (0.38) | HSP90AA1HSP90AB1ADORA2AADORA1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575340-B2 | Purine derivatives and their pharmaceutical uses | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | GLAXOSMITHKLINE LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2324025-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | Smithkline Beecham Corporation (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-2125792-B1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2125792-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | HSP90AA1 838/4885HSP90AB1 774/4885DHFR 857/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | HSP90AA1 838/4885HSP90AB1 774/4885DHFR 857/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | HSP90AA1 3107/4885HSP90AB1 3040/4885DHFR 491/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | HSP90AA1 838/4885HSP90AB1 774/4885DHFR 857/4885 |
| US-20120315291-A1 | PURINE DERIVATIVES AND THEIR PHARMACEUTICAL USES | STING1, IFNG, IRF3 | HSP90AA1 3499/4885HSP90AB1 3225/4885DHFR 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.